Gilead to invest $32 billion in US manufacturing and R&D

US antivirals giant Gilead Sciences (Nasdaq: GILD) yesterday announced a substantial investment plan, noting that it is committed to advancing world-class science and driving innovation - with the USA at the heart of its operations. Today, the firm’s US R&D and manufacturing footprint is its largest globally.

Gilead said its US R&D and manufacturing investments in the USA will create $43 billion in value to the US economy over the next five years through direct capital investment and job creation. This comprehensive investment further bolsters Gilead’s domestic research, development, and manufacturing capabilities while advancing the company’s mission to discover and develop life-changing medicines.

Gilead joins the string of big pharmas pledging mega-bucks investments in the USA. Recent examples include Bristol Myers Squibb (NYSEL BMY) with $40 billion, Novartis (NOVN: VX) with $23 billion, Eli Lilly (NYSE: LLY) with $27 billion, Roche (ROG: SIX) with $50 billion and Johnson & Johnson (NYSE: JNJ) with $55 billion. AbbVie (NYSE: ABBV) is also targeting more than $10 billion over the next decade.